2,3 Against this backdrop, oral GLP-1 receptor agonists are emerging as an increasingly important area of focus, as companies look to extend growth beyond injectables and broaden access to obesity care
Titration schedules in phase 3 trials of long acting insulin analogues incorporated individualization to allow the clinician to increase the dose to achieve optimal benefit without causing hypoglycaemia ( The oral obesity medications The oral GLP-1 based agents approved for obesity treatment deliver substantial weight loss
References: Request your Quick Start Checklist for Starting or Integrating a New GLP-1 for Weight Loss Guide.
Can I just take two 1.5mg doses to get to 3mg
It supports the bodys ability to burn fat for energy, promoting a leaner physique and aiding in weight loss efforts
Ther Adv Endocrinol Metab 1(4) 151:154 DOI: 10.1177/2042018810385052 McVeigh, J., Evans-Brown, M